Faiz Saadia A, Knox Ashley S, Fellman Bryan, Jaumally Bibi Aneesah, Pacheco G Nancy, Das Aneesa, Mathew Reeba, Murthy Rashmi, Litton Jennifer K, Balachandran Diwakar D, Bashoura Lara
Department of Pulmonary Medicine, Unit 1462, The University of Texas MD Anderson Cancer Center, P.O. Box 301402, Houston, 77030-1402, TX, USA.
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sleep Breath. 2024 Dec;28(6):2491-2500. doi: 10.1007/s11325-024-03150-w. Epub 2024 Sep 3.
Sleep disturbances are common in patients with breast cancer, but comprehensive evaluations with patient-reported outcomes (PRO) and sleep evaluation with polysomnography (PSG) are lacking. This study describes sleep disruption using PROs and PSG to identify underlying sleep disorders.
A retrospective review of patients with breast cancer undergoing formal sleep evaluation from 4/1/2009 to 7/31/2014 was performed. Clinical characteristics, PROs using Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS), and PSG data were reviewed.
404 patients were identified with 43% early, 30% locally advanced and 17% metastatic disease. PSQI revealed poor sleep in 75%, and ESS demonstrated daytime sleepiness in 55%. Sleep aid use was reported by 39%, and pain medication use in 22%. Most patients (50.2%) had multiple sleep disorders. Insomnia (54.5%) was the most frequent sleep disorder, followed closely by obstructive sleep apnea (OSA) (53.7%). PSG was performed in 74%. Multivariate analysis linked poor sleep to use of sleep aids [OR 7.7, 95% CI 3.9 to 15.2], anxiety disorder [OR 4.8, 95% CI 1.7 to 14.0], and metastatic disease [OR 2.8, 95% CI 1.1 to 6.6]. Daytime sleepiness correlated with known diagnosis of OSA [OR 1.9, 95% CI 1.0 to 3.3] and sleep aid use [OR 0.6, 95% CI 0.4 to 0.9].
Poor sleep was associated with sleep aid use, anxiety disorder and metastatic disease. Insomnia was the most common sleep disorder, followed by OSA (mostly mild). Education about sleep health and proactive screening for sleep symptoms would be beneficial in patients with breast cancer.
睡眠障碍在乳腺癌患者中很常见，但缺乏对患者报告结局（PRO）的全面评估以及多导睡眠图（PSG）睡眠评估。本研究使用PRO和PSG描述睡眠中断情况，以识别潜在的睡眠障碍。
对2009年4月1日至2014年7月31日期间接受正式睡眠评估的乳腺癌患者进行回顾性研究。回顾了临床特征、使用匹兹堡睡眠质量指数（PSQI）和爱泼华嗜睡量表（ESS）的PRO以及PSG数据。
共识别出404例患者，其中43%为早期，30%为局部晚期，17%为转移性疾病。PSQI显示75%的患者睡眠质量差，ESS显示55%的患者白天嗜睡。39%的患者报告使用助眠药物，22%的患者使用止痛药物。大多数患者（50.2%）患有多种睡眠障碍。失眠（54.5%）是最常见的睡眠障碍，其次是阻塞性睡眠呼吸暂停（OSA）（53.7%）。74%的患者进行了PSG检查。多因素分析表明，睡眠质量差与使用助眠药物[比值比（OR）7.7，95%置信区间（CI）3.9至15.2]、焦虑症[OR 4.8，95%CI 1.
